Jefferies Group’s Cytokinetics CYTK Stock Holding History

Jefferies Group’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-400	Closed	-$9K	–	1597
2020 Q3	$9K	Buy	+400	New	+$9.36K	﹤0.01%	1320

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jefferies Group's CYTK Position: Q3 2022 in Review

Jefferies Group sold out of Cytokinetics (CYTK) in Q3 2022, closing a stake of 29,550 shares — an estimated $1.16M sold.

Jefferies Group first reported a position in CYTK in Q1 2014 and held it in 8 quarters. The position peaked at $2.59M in Q3 2021. 277 funds tracked by Wall St. Rank hold CYTK as of Q3 2022.

Jefferies Group reported no remaining Cytokinetics position as of Q3 2022 after selling out during the quarter.
Jefferies Group sold 29,550 Cytokinetics shares in Q3 2022, an estimated $1.16M.
Jefferies Group first reported a position in Cytokinetics in Q1 2014 and held it in 8 quarters.
Jefferies Group's Cytokinetics position peaked at $2.59M in Q3 2021.
277 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.